Phase 2, Multicenter Open-label Basket Trial of nab-Sirolimus for Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 (PRECISION 1)

Home Phase 2, Multicenter Open-label Basket Trial of nab-Sirolimus for Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 (PRECISION 1)

Phase 2, Multicenter Open-label Basket Trial of nab-Sirolimus for Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 (PRECISION 1)

Phase 2, Multicenter Open-label Basket Trial of nab-Sirolimus for Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 (PRECISION 1)

/ Publications

Share the Post

About the Author

Related Posts

Aadi Bioscience Initiates Rolling Submission of NDA to FDA for nab-sirolimus (ABI-009, FYARRO™) for the Treatment of Advanced Malignant PEComa
Real-world analysis of patients with advanced gastrointestinal cancers harboring inactivating alterations in TSC1 and TSC2 using the Foundation Medicine genomic database
AADi Announces Licensing Agreement with Celgene for Nanotechnology-Based Drug Candidate
nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program
New Drug Trial Gives Hope for Treatment-Resistant Epilepsy
Aadi Bioscience Launches its Phase 2 Registration Trial for ABI-009PEComa
Read More
Bryan Ball
Weekly nab-Sirolimus in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa): Results From AMPECT, An Open-Label Phase 2 Registration Trial With Independent Radiology Review

Comments

Comments are closed.